Fumonisins,一组高度流行和有毒的霉菌毒素,被怀疑是动物和人类几种疾病的病原体。在动物饲料行业,伏马菌素酯酶被用作饲料添加剂,以防止伏马菌素引起的霉菌中毒。在人类中,一种流行的膳食补充剂剂型,患者对口服摄入的接受度很高,是胶囊摄取。因此,胶囊中提供的伏马菌素酯酶可能是预防人体伏马菌素中毒的有效策略。为了确定通过胶囊摄入伏马菌素酯酶的功效,在一项小规模的初步研究中,使用仔猪比较了两种应用方式。该酶口服(饲料类似物)或胃内(胶囊类似物),与伏马菌素B1(FB1)组合。FB1暴露的生物标志物;即FB1,水解FB1(HFB1)和部分水解形式(pHFB1a和pHFB1b),使用经过验证的液相色谱-串联质谱(LC-MS/MS)方法在血清和粪便中进行测量,并计算毒物动力学参数。此外,血清鞘氨醇/鞘氨醇(Sa/So)比值,影响的生物标志物,使用LC-MS/MS测定。与两种酯酶治疗相比,安慰剂组的Sa/So比率显着升高,证明酯酶的功效。此外,口服酯酶给药后,血清FB1浓度-时间曲线下面积(AUC)显著减少,粪便HFB1AUC增加.然而,在当前样本量的情况下,在胃内施用酯酶后,未观察到这些效应具有统计学意义。
Fumonisins, a group of highly prevalent and toxic mycotoxins, are suspected to be causal agents of several diseases in animals and humans. In the animal feed industry, fumonisin esterase is used as feed additive to prevent mycotoxicosis caused by fumonisins. In humans, a popular dosage form for dietary supplements, with high patient acceptance for oral intake, is capsule ingestion. Thus, fumonisin esterase provided in a capsule could be an effective strategy against fumonisin intoxication in humans. To determine the efficacy of fumonisin esterase through capsule ingestion, two modes of application were compared using piglets in a small-scale preliminary
study. The enzyme was administered intraorally (in-feed analogue) or intragastrically (capsule analogue), in combination with fumonisin B1 (FB1). Biomarkers for FB1 exposure; namely FB1, hydrolysed FB1 (HFB1) and partially hydrolysed forms (pHFB1a and pHFB1b), were measured both in serum and faeces using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, and toxicokinetic parameters were calculated. Additionally, the serum sphinganine/sphingosine (Sa/So) ratio, a biomarker of effect, was determined using LC-MS/MS. A significantly higher Sa/So ratio was shown in the placebo group compared to both esterase treatments, demonstrating the efficacy of the esterase. Moreover, a significant decrease in serum FB1 area under the concentration-time curve (AUC) and an increase of faecal HFB1 AUC were observed after intraoral esterase administration. However, these effects were not observed with statistical significance after intragastric esterase administration with the current sample size.